HC Wainwright Equities Analysts Increase Earnings Estimates for Transcat, Inc. (NASDAQ:TRNS)

Transcat, Inc. (NASDAQ:TRNS) – HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Transcat in a research note issued on Wednesday, July 31st. HC Wainwright analyst S. Buck now anticipates that the scientific and technical instruments company will earn $1.98 per share for the year, up from their prior forecast of $1.88. HC Wainwright has a “Buy” rating and a $156.00 price objective on the stock. The consensus estimate for Transcat’s current full-year earnings is $1.99 per share.

Other analysts have also issued research reports about the company. Northland Securities lowered Transcat from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 22nd. Oppenheimer raised their target price on Transcat from $125.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 22nd. Craig Hallum reduced their target price on Transcat from $150.00 to $138.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Northland Capmk lowered Transcat from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 22nd. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $151.33.

Transcat Stock Performance

Shares of TRNS opened at $111.05 on Friday. Transcat has a 12 month low of $84.45 and a 12 month high of $147.12. The stock has a fifty day moving average price of $126.72 and a 200-day moving average price of $115.73. The company has a current ratio of 3.14, a quick ratio of 2.62 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.01 billion, a PE ratio of 69.84 and a beta of 0.68.

Transcat (NASDAQ:TRNS) last issued its quarterly earnings data on Monday, July 29th. The scientific and technical instruments company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.28 by $0.20. Transcat had a return on equity of 9.23% and a net margin of 5.69%. The firm had revenue of $66.70 million during the quarter, compared to analyst estimates of $69.35 million. During the same quarter in the prior year, the business posted $0.38 EPS. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year.

Institutional Investors Weigh In On Transcat

Several institutional investors have recently bought and sold shares of TRNS. First Horizon Advisors Inc. lifted its stake in Transcat by 26.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the scientific and technical instruments company’s stock worth $72,000 after purchasing an additional 125 shares in the last quarter. Fifth Third Bancorp lifted its stake in Transcat by 95.8% in the 2nd quarter. Fifth Third Bancorp now owns 656 shares of the scientific and technical instruments company’s stock worth $79,000 after purchasing an additional 321 shares in the last quarter. Hamilton Wealth LLC purchased a new position in Transcat in the 1st quarter worth approximately $212,000. Virtu Financial LLC purchased a new position in Transcat in the 1st quarter worth approximately $224,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Transcat by 13.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,347 shares of the scientific and technical instruments company’s stock valued at $262,000 after buying an additional 284 shares during the period. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Charles P. Hadeed sold 1,358 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $130.00, for a total transaction of $176,540.00. Following the sale, the director now directly owns 21,320 shares in the company, valued at approximately $2,771,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Charles P. Hadeed sold 1,358 shares of Transcat stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $130.00, for a total value of $176,540.00. Following the sale, the director now directly owns 21,320 shares in the company, valued at approximately $2,771,600. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Lee D. Rudow sold 12,000 shares of Transcat stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $135.10, for a total value of $1,621,200.00. Following the completion of the sale, the chief executive officer now owns 91,692 shares in the company, valued at $12,387,589.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,215 shares of company stock valued at $2,969,084. Company insiders own 4.20% of the company’s stock.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.